An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton’s Tyrosine Kinase Inhibitor-Reference-Cited by-同舟云学术

An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton’s Tyrosine Kinase Inhibitor

Published:2022-06-03 Issue:4 Volume:47 Page:579-592
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

Cheng Yiming,Liu Liangang,Xue Yongjun,Zhou Simon,Li Yan

Funder

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s13318-022-00776-7.pdf

Reference28 articles.

1. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88. https://doi.org/10.1056/NEJMoa0706383.

2. Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006;176(10):5715–9. https://doi.org/10.4049/jimmunol.176.10.5715.

3. Edwards JC, Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford). 2005;44(2):151–6. https://doi.org/10.1093/rheumatology/keh446.

4. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthitis Rheum. 2003;48(6):1484–92. https://doi.org/10.1002/art.10947.

5. Küppers R. Somatic hypermutation and B cell receptor selection in normal and transformed human B cells. Ann NY Acad Sci. 2003;987:173–9. https://doi.org/10.1111/j.1749-6632.2003.tb06046.x.